Global Mirabegron Sustained-release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

According to APO Research, The global Mirabegron Sustained-release Tablets market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Mirabegron Sustained-release Tablets include Alkem Laboratories, Astellas Pharma, Lupin Pharmaceuticals, Zydus Lifesciences, China Resources Pharmaceutical, Jiangsu Huayang Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, Qilu Pharmaceutical and Shenzhen Main Luck Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Mirabegron Sustained-release Tablets, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Mirabegron Sustained-release Tablets, also provides the sales of main regions and countries. Of the upcoming market potential for Mirabegron Sustained-release Tablets, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Mirabegron Sustained-release Tablets sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Mirabegron Sustained-release Tablets market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Mirabegron Sustained-release Tablets sales, projected growth trends, production technology, application and end-user industry.

Mirabegron Sustained-release Tablets Segment by Company

Alkem Laboratories
Astellas Pharma
Lupin Pharmaceuticals
Zydus Lifesciences
China Resources Pharmaceutical
Jiangsu Huayang Pharmaceutical
Jiangxi Shanxiang Pharmaceutical
Qilu Pharmaceutical
Shenzhen Main Luck Pharmaceuticals
CSPC Pharmaceutical
Sichuan Gowell Pharmaceutical
Zhejiang Huayi Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Mirabegron Sustained-release Tablets Segment by Type

25mg per Tablet
50mg per Tablet
Mirabegron Sustained-release Tablets Segment by Application

Hospital and Clinic
Pharmacy
Other
Mirabegron Sustained-release Tablets Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mirabegron Sustained-release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mirabegron Sustained-release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mirabegron Sustained-release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mirabegron Sustained-release Tablets market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mirabegron Sustained-release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Mirabegron Sustained-release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Mirabegron Sustained-release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Mirabegron Sustained-release Tablets Market Size, 2020 VS 2024 VS 2031
1.3 Global Mirabegron Sustained-release Tablets Market Size Estimates and Forecasts (2020-2031)
1.4 Global Mirabegron Sustained-release Tablets Sales Estimates and Forecasts (2020-2031)
1.5 Global Mirabegron Sustained-release Tablets Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Mirabegron Sustained-release Tablets Market Dynamics
2.1 Mirabegron Sustained-release Tablets Industry Trends
2.2 Mirabegron Sustained-release Tablets Industry Drivers
2.3 Mirabegron Sustained-release Tablets Industry Opportunities and Challenges
2.4 Mirabegron Sustained-release Tablets Industry Restraints
3 Mirabegron Sustained-release Tablets Market by Manufacturers
3.1 Global Mirabegron Sustained-release Tablets Revenue by Manufacturers (2020-2025)
3.2 Global Mirabegron Sustained-release Tablets Sales by Manufacturers (2020-2025)
3.3 Global Mirabegron Sustained-release Tablets Average Sales Price by Manufacturers (2020-2025)
3.4 Global Mirabegron Sustained-release Tablets Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Mirabegron Sustained-release Tablets Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Mirabegron Sustained-release Tablets Manufacturers, Product Type & Application
3.7 Global Mirabegron Sustained-release Tablets Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Mirabegron Sustained-release Tablets Market CR5 and HHI
3.8.2 Global Top 5 and 10 Mirabegron Sustained-release Tablets Players Market Share by Revenue in 2024
3.8.3 2024 Mirabegron Sustained-release Tablets Tier 1, Tier 2, and Tier 3
4 Mirabegron Sustained-release Tablets Market by Type
4.1 Mirabegron Sustained-release Tablets Type Introduction
4.1.1 25mg per Tablet
4.1.2 50mg per Tablet
4.2 Global Mirabegron Sustained-release Tablets Sales by Type
4.2.1 Global Mirabegron Sustained-release Tablets Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Mirabegron Sustained-release Tablets Sales by Type (2020-2031)
4.2.3 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2020-2031)
4.3 Global Mirabegron Sustained-release Tablets Revenue by Type
4.3.1 Global Mirabegron Sustained-release Tablets Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Mirabegron Sustained-release Tablets Revenue by Type (2020-2031)
4.3.3 Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2020-2031)
5 Mirabegron Sustained-release Tablets Market by Application
5.1 Mirabegron Sustained-release Tablets Application Introduction
5.1.1 Hospital and Clinic
5.1.2 Pharmacy
5.1.3 Other
5.2 Global Mirabegron Sustained-release Tablets Sales by Application
5.2.1 Global Mirabegron Sustained-release Tablets Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Mirabegron Sustained-release Tablets Sales by Application (2020-2031)
5.2.3 Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2020-2031)
5.3 Global Mirabegron Sustained-release Tablets Revenue by Application
5.3.1 Global Mirabegron Sustained-release Tablets Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Mirabegron Sustained-release Tablets Revenue by Application (2020-2031)
5.3.3 Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2020-2031)
6 Global Mirabegron Sustained-release Tablets Sales by Region
6.1 Global Mirabegron Sustained-release Tablets Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Mirabegron Sustained-release Tablets Sales by Region (2020-2031)
6.2.1 Global Mirabegron Sustained-release Tablets Sales by Region (2020-2025)
6.2.2 Global Mirabegron Sustained-release Tablets Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Mirabegron Sustained-release Tablets Revenue by Region
7.1 Global Mirabegron Sustained-release Tablets Revenue by Region
7.1.1 Global Mirabegron Sustained-release Tablets Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Mirabegron Sustained-release Tablets Revenue by Region (2020-2025)
7.1.3 Global Mirabegron Sustained-release Tablets Revenue by Region (2026-2031)
7.1.4 Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Mirabegron Sustained-release Tablets Revenue (2020-2031)
7.2.2 North America Mirabegron Sustained-release Tablets Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Mirabegron Sustained-release Tablets Revenue (2020-2031)
7.3.2 Europe Mirabegron Sustained-release Tablets Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Mirabegron Sustained-release Tablets Revenue (2020-2031)
7.4.2 Asia-Pacific Mirabegron Sustained-release Tablets Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Mirabegron Sustained-release Tablets Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Mirabegron Sustained-release Tablets Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Alkem Laboratories
8.1.1 Alkem Laboratories Comapny Information
8.1.2 Alkem Laboratories Business Overview
8.1.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio
8.1.5 Alkem Laboratories Recent Developments
8.2 Astellas Pharma
8.2.1 Astellas Pharma Comapny Information
8.2.2 Astellas Pharma Business Overview
8.2.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio
8.2.5 Astellas Pharma Recent Developments
8.3 Lupin Pharmaceuticals
8.3.1 Lupin Pharmaceuticals Comapny Information
8.3.2 Lupin Pharmaceuticals Business Overview
8.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
8.3.5 Lupin Pharmaceuticals Recent Developments
8.4 Zydus Lifesciences
8.4.1 Zydus Lifesciences Comapny Information
8.4.2 Zydus Lifesciences Business Overview
8.4.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio
8.4.5 Zydus Lifesciences Recent Developments
8.5 China Resources Pharmaceutical
8.5.1 China Resources Pharmaceutical Comapny Information
8.5.2 China Resources Pharmaceutical Business Overview
8.5.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
8.5.5 China Resources Pharmaceutical Recent Developments
8.6 Jiangsu Huayang Pharmaceutical
8.6.1 Jiangsu Huayang Pharmaceutical Comapny Information
8.6.2 Jiangsu Huayang Pharmaceutical Business Overview
8.6.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
8.6.5 Jiangsu Huayang Pharmaceutical Recent Developments
8.7 Jiangxi Shanxiang Pharmaceutical
8.7.1 Jiangxi Shanxiang Pharmaceutical Comapny Information
8.7.2 Jiangxi Shanxiang Pharmaceutical Business Overview
8.7.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
8.7.5 Jiangxi Shanxiang Pharmaceutical Recent Developments
8.8 Qilu Pharmaceutical
8.8.1 Qilu Pharmaceutical Comapny Information
8.8.2 Qilu Pharmaceutical Business Overview
8.8.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
8.8.5 Qilu Pharmaceutical Recent Developments
8.9 Shenzhen Main Luck Pharmaceuticals
8.9.1 Shenzhen Main Luck Pharmaceuticals Comapny Information
8.9.2 Shenzhen Main Luck Pharmaceuticals Business Overview
8.9.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
8.9.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
8.10 CSPC Pharmaceutical
8.10.1 CSPC Pharmaceutical Comapny Information
8.10.2 CSPC Pharmaceutical Business Overview
8.10.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
8.10.5 CSPC Pharmaceutical Recent Developments
8.11 Sichuan Gowell Pharmaceutical
8.11.1 Sichuan Gowell Pharmaceutical Comapny Information
8.11.2 Sichuan Gowell Pharmaceutical Business Overview
8.11.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
8.11.5 Sichuan Gowell Pharmaceutical Recent Developments
8.12 Zhejiang Huayi Pharmaceutical
8.12.1 Zhejiang Huayi Pharmaceutical Comapny Information
8.12.2 Zhejiang Huayi Pharmaceutical Business Overview
8.12.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
8.12.5 Zhejiang Huayi Pharmaceutical Recent Developments
8.13 Chia Tai Tianqing Pharmaceutical
8.13.1 Chia Tai Tianqing Pharmaceutical Comapny Information
8.13.2 Chia Tai Tianqing Pharmaceutical Business Overview
8.13.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
8.13.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Mirabegron Sustained-release Tablets Value Chain Analysis
9.1.1 Mirabegron Sustained-release Tablets Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Mirabegron Sustained-release Tablets Production Mode & Process
9.2 Mirabegron Sustained-release Tablets Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Mirabegron Sustained-release Tablets Distributors
9.2.3 Mirabegron Sustained-release Tablets Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings